News & Media

Swiss Rockets Announces Strategic Exclusive License Acquisition of Cutting-Edge Sequencing Technology from MGI Tech and Complete Genomics

Swiss Rockets and Squirro Announce Strategic Partnership to Accelerate AI Transformation in Biotechnology

Swiss Rockets Serbia Signs Joint Declaration of Intent with European Commission and Development Agency of Serbia to Establish Regional Centre of Excellence for Precision Medicine

Swiss Rockets Signs Strategic Exclusive Licensing Agreement with MGI and Complete Genomics, Subject to MGI Shareholder Approval

Bimiralisib, Topical PI3K/mTOR Inhibitor Shows Up To 92% Clearance Rate And Superior Tolerability In Proof-Of-Concept Actinic Keratosis Study

Swiss Rockets Welcomes Former Genentech Business Development Executive Thomas Zioncheck as Chief Strategy Officer

In the Spotlight: A Personal Side of Our CEO

Swiss Rockets Featured in Finanz und Wirtschaft: Strong Industry Recognition and Promising Clinical Outlook

Featured Article in Global Family Office Journal – A Proud Moment for Swiss Rockets

Rocketvax Achieves Major Breakthrough in Live-Attenuated SARS-CoV-2 Vaccine Development

Swiss Rockets AG Announces Key Appointments to Leadership Team

Torpedo Pharmaceuticals AG’s Mission is to set a New Standard in Cancer Therapy with Innovative Radiopharmaceuticals

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

Torqur AG Presents Interim Phase 2 Clinical Trial Results at American Academy of Dermatology

Spotlight on Leadership: Dr. Vladimir Cmiljanovic in The CEO Magazine